Open Access

Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review)

  • Authors:
    • Cristiana Tanase
    • Ionela Daniela Popescu
    • Ana‑Maria Enciu
    • Ancuta Augustina Gheorghisan‑Galateanu
    • Elena Codrici
    • Simona Mihai
    • Lucian Albulescu
    • Laura Necula
    • Radu Albulescu
  • View Affiliations

  • Published online on: November 19, 2018     https://doi.org/10.3892/ol.2018.9734
  • Pages: 4060-4067
  • Copyright: © Tanase et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neoangiogenesis plays an important role in cutaneous lymphoma pathogenesis. Cutaneous T‑cell lymphoma (CTCL) is characterized by the presence of malignant T‑cell clones in the skin. Vascular microenvironment of lymphomas accelerates neoangiogenesis through several factors released by tumoral cells: VEGF family, bFGF and PIGF. Tumor stroma (fibroblasts, inflammatory and immune cells) also plays a crucial role, by providing additional angiogenic factors. The angiogenic process through the VEGF‑VEGFR axis can promote survival, proliferation and metastasis via autocrine mechanisms in cutaneous lymphomas. Microvascular density (MVD) measures the neo‑vascularization of cutaneous lymphoma, generated by the response of tumor cells, proangiogenic stromal cells, and benign T/B lymphocytes within the tumor inflammatory infiltrate. Pro‑angiogenic proteins have been found to indicate the evolution and prognosis in patients with CTCL. In conclusion, anti‑angiogenic therapeutic protocols can target tumor vasculature or malignant tumor cells directly or through a large number of combinations with other drugs. The integration of proteomics into clinical practice based on high‑throughput technologies leads to the development of personalized medicine, adapting the specific biomarkers to the application of cancer‑type specific individual drug targets.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanase C, Popescu ID, Enciu AM, Gheorghisan‑Galateanu AA, Codrici E, Mihai S, Albulescu L, Necula L and Albulescu R: Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review). Oncol Lett 17: 4060-4067, 2019
APA
Tanase, C., Popescu, I.D., Enciu, A., Gheorghisan‑Galateanu, A.A., Codrici, E., Mihai, S. ... Albulescu, R. (2019). Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review). Oncology Letters, 17, 4060-4067. https://doi.org/10.3892/ol.2018.9734
MLA
Tanase, C., Popescu, I. D., Enciu, A., Gheorghisan‑Galateanu, A. A., Codrici, E., Mihai, S., Albulescu, L., Necula, L., Albulescu, R."Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review)". Oncology Letters 17.5 (2019): 4060-4067.
Chicago
Tanase, C., Popescu, I. D., Enciu, A., Gheorghisan‑Galateanu, A. A., Codrici, E., Mihai, S., Albulescu, L., Necula, L., Albulescu, R."Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review)". Oncology Letters 17, no. 5 (2019): 4060-4067. https://doi.org/10.3892/ol.2018.9734